Brokerages Expect Oxford Immunotec Global PLC (NASDAQ:OXFD) Will Post Quarterly Sales of $19.65 Million

Wall Street analysts expect that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce $19.65 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Oxford Immunotec Global’s earnings. The highest sales estimate is $19.83 million and the lowest is $19.47 million. Oxford Immunotec Global reported sales of $18.11 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.5%. The firm is scheduled to report its next quarterly earnings report on Monday, March 1st.

On average, analysts expect that Oxford Immunotec Global will report full-year sales of $58.83 million for the current fiscal year, with estimates ranging from $58.65 million to $59.01 million. For the next financial year, analysts forecast that the business will post sales of $82.90 million, with estimates ranging from $81.49 million to $84.31 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $19.44 million for the quarter, compared to the consensus estimate of $18.58 million. Oxford Immunotec Global had a negative return on equity of 7.52% and a negative net margin of 28.12%.

Several research analysts have recently issued reports on the company. TheStreet raised Oxford Immunotec Global from a “d” rating to a “c-” rating in a research report on Monday, November 23rd. JPMorgan Chase & Co. cut Oxford Immunotec Global from an “overweight” rating to a “neutral” rating in a report on Thursday, January 7th. BidaskClub upgraded Oxford Immunotec Global from a “hold” rating to a “buy” rating in a report on Friday, December 18th. Piper Sandler cut Oxford Immunotec Global from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $24.00 to $22.00 in a report on Thursday, January 7th. Finally, Zacks Investment Research upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Wednesday, November 4th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Oxford Immunotec Global presently has a consensus rating of “Hold” and a consensus price target of $18.50.

Hedge funds have recently modified their holdings of the business. Advisor Group Holdings Inc. raised its holdings in shares of Oxford Immunotec Global by 61.3% during the second quarter. Advisor Group Holdings Inc. now owns 14,294 shares of the company’s stock valued at $186,000 after buying an additional 5,430 shares during the last quarter. Engineers Gate Manager LP grew its holdings in shares of Oxford Immunotec Global by 78.9% during the 2nd quarter. Engineers Gate Manager LP now owns 18,311 shares of the company’s stock valued at $238,000 after acquiring an additional 8,074 shares in the last quarter. PDT Partners LLC purchased a new position in shares of Oxford Immunotec Global during the 2nd quarter valued at $372,000. ExodusPoint Capital Management LP acquired a new stake in shares of Oxford Immunotec Global in the 3rd quarter valued at $401,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Oxford Immunotec Global in the 3rd quarter valued at $454,000. Institutional investors own 90.17% of the company’s stock.

Oxford Immunotec Global stock traded down $0.20 during trading on Wednesday, reaching $22.00. 2,554,157 shares of the company were exchanged, compared to its average volume of 2,912,970. Oxford Immunotec Global has a 52-week low of $8.37 and a 52-week high of $23.11. The company has a market capitalization of $571.16 million, a P/E ratio of -34.92 and a beta of 1.17. The stock’s 50 day simple moving average is $17.02 and its two-hundred day simple moving average is $14.03.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Further Reading: What does a neutral rating on stocks mean?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.